Belantamab Mafodotin: BCMA ADC Mechanism and the MMAF Payload
Belantamab mafodotin (Blenrep) is an antibody-drug conjugate (ADC) developed by GSK that targets BCMA — B-cell maturation antigen — a protein selectively expressed on malignant plasma cells in multiple myeloma. The ADC architecture links a humanised anti-BCMA antibody to monomethyl auristatin F (MMAF), a microtubule-disrupting cytotoxic payload, delivering targeted cell death to BCMA-expressing tumour cells while limiting systemic toxicity relative to conventional chemotherapy.
BCMA’s selective expression on plasma cells — and its near-universal presence on myeloma cells — makes it one of the most validated targets in haematological oncology. According to clinical data registries monitored by ClinicalTrials.gov, BCMA-directed therapies now span three distinct modalities: ADCs such as belantamab mafodotin, bispecific T-cell engagers, and CAR-T cell therapies, each with distinct mechanisms of action, safety profiles, and combination potential.
Belantamab mafodotin (Blenrep) is an anti-BCMA antibody-drug conjugate developed by GSK that delivers an MMAF (monomethyl auristatin F) cytotoxic payload to BCMA-expressing myeloma plasma cells, inducing microtubule disruption and cell death.
The ADC design is clinically significant because it enables tumour-selective cytotoxicity without requiring T-cell activation — a meaningful distinction from bispecific antibodies and CAR-T therapies that depend on functional T-cell compartments. This immunological independence positions belantamab mafodotin as a viable option in heavily pre-treated patients with compromised immune function, a common feature of relapsed/refractory multiple myeloma.
BCMA is a cell-surface receptor encoded by the TNFRSF17 gene, expressed predominantly on mature B cells and plasma cells. In multiple myeloma, BCMA is highly and uniformly expressed on malignant plasma cells, making it a tumour-selective target for ADCs, bispecific antibodies, and CAR-T therapies. Its restricted normal-tissue expression reduces the risk of on-target, off-tumour toxicity compared with broader targets such as CD38.
The DREAMM Programme: Phase III Combination Strategies
The DREAMM (DRiving Excellence in Approaches to Multiple Myeloma) clinical programme is GSK’s structured development series for belantamab mafodotin, encompassing multiple Phase I, II, and III trials evaluating the agent across lines of therapy and combination partners. Phase III trials within the programme — notably DREAMM-7 and DREAMM-8 — are designed to establish belantamab mafodotin’s role in combination regimens against active comparator arms in relapsed/refractory multiple myeloma.
The DREAMM Phase III programme includes DREAMM-7, which evaluates belantamab mafodotin combined with bortezomib and dexamethasone, and DREAMM-8, which evaluates belantamab mafodotin combined with pomalidomide and dexamethasone, both in patients with relapsed/refractory multiple myeloma.
DREAMM-7: Belantamab + Bortezomib + Dexamethasone
DREAMM-7 evaluates the triplet combination of belantamab mafodotin with bortezomib — a proteasome inhibitor — and dexamethasone against a comparator arm of daratumumab, bortezomib, and dexamethasone (DVd). This head-to-head design is strategically significant: it directly pits GSK’s BCMA ADC against Janssen’s anti-CD38 antibody within the same backbone regimen, generating comparative efficacy data in a setting where both agents have established clinical activity.
DREAMM-8: Belantamab + Pomalidomide + Dexamethasone
DREAMM-8 tests belantamab mafodotin with pomalidomide — an immunomodulatory drug (IMiD) — and dexamethasone against a comparator of bortezomib, pomalidomide, and dexamethasone. The IMiD backbone is widely used in relapsed/refractory myeloma, and the DREAMM-8 design tests whether adding BCMA-directed cytotoxicity to an IMiD platform improves outcomes over a standard-of-care proteasome inhibitor combination.
“The DREAMM-7 trial design — belantamab mafodotin versus daratumumab within the same bortezomib-dexamethasone backbone — represents one of the most direct head-to-head confrontations between BCMA-directed and CD38-directed strategies in relapsed/refractory myeloma.”
Belantamab mafodotin was initially withdrawn from the EU and US markets following conditional approval, pending confirmatory Phase III data. The DREAMM Phase III programme represents GSK’s evidence-generation strategy for regulatory resubmission and expanded approval, making these readouts commercially and strategically critical for the asset’s future.
Track DREAMM trial readouts, BCMA patent filings, and GSK pipeline intelligence in real time.
Explore BCMA Intelligence in PatSnap Eureka →GSK vs. Daratumumab: Competing Combination Regimen Strategies
Daratumumab (Darzalex), developed by Janssen, is an anti-CD38 monoclonal antibody with one of the broadest combination approval profiles in multiple myeloma, spanning frontline through heavily pre-treated relapsed/refractory settings. While daratumumab targets CD38 rather than BCMA, both agents compete directly for use in the same patient populations and within overlapping combination backbones — making the DREAMM-7 head-to-head comparison a pivotal commercial and scientific event.
Daratumumab (Darzalex) is an anti-CD38 monoclonal antibody developed by Janssen with multiple approved combination regimens across myeloma treatment lines; DREAMM-7 directly compares belantamab mafodotin against daratumumab within the same bortezomib-dexamethasone backbone in relapsed/refractory multiple myeloma.
The competitive dynamics extend beyond a single trial. Daratumumab’s subcutaneous formulation (Darzalex Faspro), its established real-world safety profile, and its deep penetration into frontline combinations mean that belantamab mafodotin must demonstrate differentiated clinical benefit — not merely non-inferiority — to carve a durable commercial position. GSK’s strategy appears to rest on BCMA-specificity, ADC mechanism, and combination flexibility as points of differentiation.
The IP dimension is equally contested. Patent filings from GSK, Janssen, and their respective licensors cover antibody sequences, ADC linker-payload configurations, combination regimen methods-of-use, and patient selection biomarkers. According to WIPO patent databases, BCMA-directed therapeutics represent one of the most active areas of oncology patenting, with assignee activity spanning originator companies, academic institutions, and biosimilar developers.
Daratumumab Biosimilar Entrants and Combination IP
Daratumumab’s loss of exclusivity timeline is attracting biosimilar development activity, which could alter the competitive calculus for belantamab mafodotin. If daratumumab-based combinations become accessible at lower cost through biosimilar entrants, the value proposition of a branded BCMA ADC in the same treatment line will depend increasingly on demonstrated efficacy superiority. This dynamic is tracked by analysts using patent expiry data and regulatory filing records available through platforms such as PatSnap’s pharmaceutical intelligence suite.
Bispecific Antibodies Enter the BCMA Arena
Teclistamab (Janssen) and elranatamab (Pfizer) are BCMA-directed bispecific antibodies that engage both BCMA on myeloma cells and CD3 on T cells, redirecting cytotoxic T-cell activity against the tumour. Both agents have received regulatory approvals for relapsed/refractory multiple myeloma and represent a distinct mechanistic class from belantamab mafodotin’s ADC approach.
Teclistamab (developed by Janssen) and elranatamab (developed by Pfizer) are BCMA-directed bispecific antibodies approved for relapsed/refractory multiple myeloma; both engage BCMA on tumour cells and CD3 on T cells to redirect T-cell-mediated killing, competing with belantamab mafodotin in overlapping patient populations.
The entry of bispecific antibodies into the BCMA space has materially complicated GSK’s competitive position. Unlike ADCs, bispecific antibodies do not require conjugation chemistry or payload management, and their off-the-shelf availability (as opposed to CAR-T’s autologous manufacturing) positions them as accessible options in community oncology settings. According to clinical data published via The New England Journal of Medicine, both teclistamab and elranatamab have demonstrated meaningful response rates in heavily pre-treated myeloma populations.
BCMA bispecific antibodies (teclistamab, elranatamab) require functional T cells to exert cytotoxicity, as they act by redirecting T-cell killing. Belantamab mafodotin, as an ADC, delivers cytotoxic payload directly to BCMA-expressing cells without T-cell dependence. This distinction may influence patient selection in heavily immunosuppressed or T-cell-depleted myeloma populations.
The competitive landscape also includes BCMA-directed CAR-T therapies — idecabtagene vicleucel (ide-cel, Bristol Myers Squibb) and ciltacabtagene autoleucel (cilta-cel, Janssen/Legend Biotech) — which have demonstrated deep and durable responses but are constrained by manufacturing complexity and access limitations. The interplay between these modalities is shaping treatment sequencing guidelines and IP strategy across the sector.
Map the full BCMA competitive landscape — ADCs, bispecifics, and CAR-T — with PatSnap Eureka’s AI-powered drug intelligence.
Analyse the BCMA Landscape in PatSnap Eureka →IP Landscape: Patent Dimensions Across the BCMA Race
The BCMA intellectual property landscape spans multiple patent dimensions that analysts must navigate to understand freedom-to-operate, competitive positioning, and lifecycle management strategies for both belantamab mafodotin and its competitors. Key patent families cover anti-BCMA antibody sequences and binding epitopes, ADC linker-payload configurations (including MMAF conjugation chemistry), combination regimen methods-of-use, and patient selection biomarkers for BCMA expression.
Recommended Search Dimensions for BCMA Patent Intelligence
For analysts conducting patent landscape analysis on this topic, the following search dimensions are recommended across major patent offices including EPO, USPTO, and WIPO:
- BCMA ADC mechanism and reformulation: Query terms including “belantamab mafodotin”, “BCMA antibody-drug conjugate”, “MMAF payload”, “anti-BCMA ADC formulation” across patent databases
- DREAMM Phase III readouts: Academic literature queries for “DREAMM-7”, “DREAMM-8”, “belantamab bortezomib dexamethasone”, “belantamab pomalidomide” in PubMed and clinical trial registries
- BCMA competitive landscape: Queries covering “daratumumab BCMA”, “teclistamab”, “elranatamab”, “BCMA CAR-T myeloma”, “bispecific antibody multiple myeloma Phase III” with assignee filters for GSK, Janssen, Pfizer, Bristol Myers Squibb
- Biosimilar and combination IP: Daratumumab biosimilar filings, combination regimen patents, and patient selection biomarker claims across originator and generic assignees
BCMA-directed therapeutics represent one of the most active areas of oncology patenting, with key patent dimensions covering anti-BCMA antibody sequences, ADC linker-payload configurations, combination regimen methods-of-use, and patient selection biomarkers across assignees including GSK, Janssen, Pfizer, and Bristol Myers Squibb.
Multiple myeloma remains a largely incurable plasma cell malignancy with significant unmet need, particularly in relapsed/refractory settings where patients have exhausted prior lines including proteasome inhibitors and immunomodulatory drugs. The density of BCMA-directed IP filings reflects the commercial importance of this unmet need and the competitive intensity among originator companies seeking durable market positions.
Analysts tracking this space through platforms such as PatSnap’s life sciences intelligence tools can monitor assignee filing activity, claim scope evolution, and freedom-to-operate signals across the full BCMA patent landscape — from antibody sequence patents through to combination regimen and formulation filings that govern commercial strategy well beyond initial approval.